<DOC>
	<DOCNO>NCT02693613</DOCNO>
	<brief_summary>The objective study evaluate effect Kremezin® pharmacokinetics single dose ASP1517 healthy non-elderly adult male subject administer concomitantly time separated manner .</brief_summary>
	<brief_title>Pharmacokinetic Study ASP1517 With Kremezin®</brief_title>
	<detailed_description />
	<criteria>Body weight ( screen ) : ≥50.0 kg &lt; 80.0 kg Bodymass index ( BMI ) ( screen ) : ≥17.6 &lt; 26.4 kg/m2 Subject must agree use contraception consist two establish form ( 1 must barrier method ) start time informed consent continue throughout treatment period 84days ASP1517 administration last period : Subject must agree donate sperm start time informed consent continue throughout 84 day last administration ASP1517 last period . Received schedule receive investigational drug clinical trial postmarketing study within 120 day screen period screen hospital admission day Period 1 ( Day −1 ) . Received scheduled receive medication ( include overthecounter [ OTC ] drug ) within 7 day hospital admission day Period 1 ( Day −1 ) . Received scheduled receive supplement within 7 day hospital admission day Period 1 ( Day −1 ) . Deviates normal range blood pressure , pulse rate , body temperature standard 12lead electrocardiogram ( ECG ) specify screen hospital admission day Period 1 ( Day −1 ) . Meets follow criterion laboratory test screen hospital admission day Period 1 ( Day −1 ) . Normal range test specify study site test/assay organization use normal range study . Concurrent previous drug allergy . Development ( ) upper gastrointestinal symptom within seven day hospital admission day Period 1 ( Day −1 ) . Concurrent previous hepatic disease , heart disease , respiratory disease , gastrointestinal disease , gastrointestinal obstruction , oesophageal varix , renal disease , endocrine disease , cerebrovascular disorder , malignant tumor , retinal neovascular lesion macular edema . Concurrent chronic constipation diarrhoea . A history digestive tract excision . Previous use hypoxia inducible factorprolyl hydroxylase inhibitor ( HIFPHI ) ASP1517 ( FG4592 ) , YM311 ( FG2216 ) erythropoietin product . Excessive alcohol smoking habit .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Kremezin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP1517</keyword>
</DOC>